Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 3
2009 5
2010 1
2012 1
2013 1
2014 4
2016 1
2017 1
2019 5
2020 2
2021 6
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Targeting CDK2 in cancer: challenges and opportunities for therapy.
Tadesse S, Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, Wang S. Tadesse S, et al. Among authors: portman n. Drug Discov Today. 2020 Feb;25(2):406-413. doi: 10.1016/j.drudis.2019.12.001. Epub 2019 Dec 10. Drug Discov Today. 2020. PMID: 31839441 Review.
Epigenetic Therapies and Biomarkers in Breast Cancer.
Brown LJ, Achinger-Kawecka J, Portman N, Clark S, Stirzaker C, Lim E. Brown LJ, et al. Among authors: portman n. Cancers (Basel). 2022 Jan 18;14(3):474. doi: 10.3390/cancers14030474. Cancers (Basel). 2022. PMID: 35158742 Free PMC article. Review.
Pushing estrogen receptor around in breast cancer.
Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C. Lim E, et al. Among authors: portman n. Endocr Relat Cancer. 2016 Dec;23(12):T227-T241. doi: 10.1530/ERC-16-0427. Epub 2016 Oct 11. Endocr Relat Cancer. 2016. PMID: 27729416 Review.
A new sophistication for breast cancer PDXs.
Portman N, Lim E. Portman N, et al. Nat Cancer. 2022 Feb;3(2):138-140. doi: 10.1038/s43018-021-00328-z. Nat Cancer. 2022. PMID: 35221337 No abstract available.
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.
Karimi L, Alves CL, Terp MG, Tuttolomondo M, Portman N, Ehmsen S, Johansen LE, Bak M, Lim E, Ditzel HJ. Karimi L, et al. Among authors: portman n. Cancer Commun (Lond). 2023 Jun;43(6):720-725. doi: 10.1002/cac2.12425. Epub 2023 Apr 26. Cancer Commun (Lond). 2023. PMID: 37101393 Free PMC article. No abstract available.
32 results